Last reviewed · How we verify
Levomethamphetamine (LEVMETAMFETAMINE)
At a glance
| Generic name | LEVMETAMFETAMINE |
|---|---|
| Drug class | levmetamfetamine |
| Target | Trace amine-associated receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| Annual revenue | 172 |
Approved indications
- Nasal congestion
Common side effects
Key clinical trials
- Factors Affecting Methamphetamine and Opiates Drug Testing (PHASE1)
- Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levomethamphetamine CI brief — competitive landscape report
- Levomethamphetamine updates RSS · CI watch RSS